Thus, HDAC and proteasome inhibitors and the MK1775 inhibitor share cell cycle disruption as a mechanism, perhaps suggesting that osteosarcoma is remarkably vulnerable to this particular perturbation. The gene discussed is HDAC9; the disease is osteosarcoma.